NJ Tech Council CFO Forum – An Overview of the Amneal/Impax Merger

Today I had the privilege of attending the NJ Tech Council CFO Forum at EY in Iselin (Metropark), NJ.  The featured speaker was Jim Mastakas (bio), the current Senior VP and CFO of Virtus Pharmaceuticals, and who previously worked at Amneal.  Jim was there to speak about his time at Amneal and the deal he … Continue reading NJ Tech Council CFO Forum – An Overview of the Amneal/Impax Merger

How Changing the Reporting Period for Public Companies to Semiannual Could Impact the D&O Market

Last week the issue of public companies having to do quarterly reports popped up in the news in a big way with the President tweeting and then speaking on the possibility of ending quarterly reporting.  There are a lot of opinions out there on whether this is a good idea or bad idea.  Some people … Continue reading How Changing the Reporting Period for Public Companies to Semiannual Could Impact the D&O Market

Why Securities Class Filings are a Reality for Publicly Traded Companies

Cornerstone Research always puts out great data and this report on Securities Class Action Filings for the first half of 2018 is no exception.  I recommend you check out the full report which you can find here. These visuals really speak for themselves but the big takeaway is that if you are publicly traded company … Continue reading Why Securities Class Filings are a Reality for Publicly Traded Companies

Tuesday Morning Reads

It's Tuesday and this is what I'm reading this morning: What is a p-Value? Not Even Scientists Can Easily Explain P-values Sticker Shock: The Real Cost Of America's 10 Most Expensive Drugs The Dementia Discovery Fund (DDF) completed its fundraising Monday, raising $350 million. The VC fund, backed by various entities, including government departments, Big Pharma, … Continue reading Tuesday Morning Reads